10-Q: Kodiak Sciences Faces Going Concern Doubt Amid Rising Losses

Kodiak Sciences reported substantial net losses and negative cash flows, raising significant doubt about its ability to continue as a going concern, despite ongoing clinical trial progress for its retinal disease therapies.

Summary

• Kodiak Sciences Inc. reported a net loss of $173.2 million for the nine months ended September 30, 2025, an increase from $132.1 million for the same period in 2024.
• The company's cash and cash equivalents decreased to $72.0 million as of September 30, 2025, from $168.1 million at December 31, 2024.
• Net cash used in operating activities was $96.6 million for the nine months ended September 30, 2025, compared to $87.2 million for the same period in 2024.
• Research and development expenses increased by $42.6 million to $136.9 million for the nine months ended September 30, 2025, driven by increased activities for tarcocimab, KSI-501, KSI-101, and ABC Platform programs.
• General and administrative expenses decreased by $6.3 million to $40.1 million for the nine months ended September 30, 2025, primarily due to lower stock compensation and net rent expense, partially offset by a $1.9 million non-cash lease impairment.
• The company has an accumulated deficit of $1,502 million as of September 30, 2025.
• Kodiak's management has expressed substantial doubt about its ability to continue as a going concern, citing insufficient cash to meet anticipated operating and capital expenditure requirements for the next 12 months.
• Tarcocimab, the lead investigational medicine, has completed enrollment for Phase 3 GLOW2 (diabetic retinopathy) and DAYBREAK (wet age-related macular degeneration) studies, with topline data expected in 1Q 2026 and 3Q 2026, respectively.
• KSI-501, an anti-IL-6, VEGF-trap bispecific therapy, has completed enrollment in the Phase 3 DAYBREAK study for wet AMD, with topline data expected in 3Q 2026.
• KSI-101, a bispecific protein targeting IL-6 and VEGF for macular edema secondary to inflammation (MESI), is actively enrolling patients in Phase 3 PEAK and PINNACLE studies, with topline data expected in 4Q 2026 and 1Q 2027, respectively.
• The company subleased its building at 1200 Page Mill Road, recognizing $4.2 million in sublease income for the nine months ended September 30, 2025, and a $1.9 million non-cash lease impairment expense in Q1 2025.

Sentiment

Score: 2

Explanation: The company faces severe financial challenges, including substantial and increasing net losses, a rapidly depleting cash reserve, and an explicit 'going concern' warning. While clinical programs are progressing, past failures and the highly competitive market for retinal diseases add significant risk. The need for immediate and substantial capital raises in an uncertain economic environment further compounds the negative outlook.

Positives

• All three lead clinical programs (tarcocimab, KSI-501, KSI-101) are progressing, with GLOW2 and DAYBREAK studies having completed enrollment.
• Tarcocimab has demonstrated strong efficacy in prior GLOW1 (DR) and BEACON (RVO) studies, and non-inferior efficacy in DAYLIGHT (wet AMD).
• KSI-101's Phase 1b APEX study showed meaningful visual and anatomical gains in both DME and MESI, with a favorable safety profile, leading to advancement into Phase 3 studies.
• The company is advancing its ABC Platform and ABCD Platform for new pipeline programs, including dual cytokine-targeting bispecific antibodies and therapies for glaucoma and geographic atrophy.
• Development of the VETi (Visual Engagement Technology and imager) program, an AIand machine-learning-enabled wearable headset, is progressing with advancements in hardware, software, and algorithms.

Negatives

• The company reported a significant increase in net loss, reaching $173.2 million for the nine months ended September 30, 2025, compared to $132.1 million in the prior year.
• Cash and cash equivalents declined substantially to $72.0 million from $168.1 million, indicating a rapid burn rate.
• Net cash used in operating activities increased to $96.6 million, demonstrating higher operational cash outflows.
• Management has explicitly stated 'substantial doubt' about the company's ability to continue as a going concern, as existing cash may not be sufficient for the next 12 months.
• Prior Phase 2b/3 DAZZLE and Phase 3 GLEAM and GLIMMER clinical trials for tarcocimab failed to meet their primary efficacy endpoints, with an unexpected increase in cataracts observed.
• The company has never generated any revenue from product sales and does not anticipate doing so for several years, if at all.

Risks

• The company is in the clinical stage of drug development with a very limited operating history and no products approved for commercial sale, making future success and viability difficult to evaluate.
• Significant net losses have been incurred since inception, and the company anticipates continued significant and increasing net losses for the foreseeable future.
• The company's financial condition raises substantial doubt about its ability to continue as a going concern.
• Failure to obtain additional financing may prevent the completion of development and commercialization of product candidates.
• Drug development is highly uncertain and involves substantial risk; the company has never generated product sales revenue and may never be profitable.
• Prospects are heavily dependent on tarcocimab, KSI-501, and KSI-101, which are in clinical development, and previous clinical trial results are not necessarily predictive of future success.
• Failure of pivotal studies of tarcocimab to meet primary efficacy endpoints may lead to pausing, changing, or discontinuing development of other ABC Platform candidates.
• Research and development of biopharmaceutical products is inherently risky, with no assurance of regulatory approval for any product candidates.
• Limited resources necessitate prioritizing development of certain product candidates, potentially expending resources on unsuccessful candidates and missing more profitable opportunities.
• Substantial delays in clinical trials may occur due to various factors, including patient enrollment difficulties, regulatory requirements, or adverse events.
• Clinical trials may fail to demonstrate substantial evidence of durability, efficacy, and safety, preventing, delaying, or limiting regulatory approval and commercialization.
• Product candidates may cause undesirable side effects or have other properties that could halt development, prevent approval, limit commercial potential, or result in negative consequences (e.g., cataracts observed with tarcocimab).
• Significant competition exists in an environment of rapid technological and scientific change, with competitors potentially retaining market share, achieving earlier approval, or developing superior therapies.
• The regulatory approval processes are lengthy, time-consuming, and unpredictable, potentially preventing product revenue generation.
• Reliance on third parties to conduct clinical trials, research, and preclinical testing carries risks of unsatisfactory performance or missed deadlines.
• Reliance on third parties for manufacturing materials for product candidates and clinical trials increases the risk of insufficient quantities, unacceptable costs, or supply disruptions, especially with single-source suppliers.
• Inability to obtain and maintain patent protection for product candidates or the ABC Platform could allow competitors to commercialize similar products.
• High dependence on key personnel; failure to attract, motivate, and retain qualified personnel could hinder business strategy implementation.
• Growth in organization size and capabilities may be difficult to manage, imposing significant responsibilities on management.
• Information technology systems, or those of third parties, are vulnerable to cyberattacks and security incidents, potentially leading to adverse consequences.
• Business activities may be subject to the Foreign Corrupt Practices Act (FCPA) and similar anti-bribery and anti-corruption laws.
• Failure to comply with healthcare laws could result in substantial penalties.
• Disruptions at the FDA and other government agencies due to funding shortages or shutdowns could hinder timely review and approval.
• Healthcare legislative measures aimed at reducing costs (e.g., IRA, OBBBA) may negatively impact the commercial viability and pricing of product candidates.
• International operations are subject to economic, political, regulatory, and other risks, including trade policies, tariffs, and foreign currency exchange rate fluctuations.
• Disease outbreaks, epidemics, and pandemics could materially and adversely affect business and operations, including clinical trials and supply chains.
• Ability to use net operating loss carryforwards and other tax attributes may be limited by ownership changes or tax law changes (e.g., Sections 382 and 383 of the Code, Tax Act, CARES Act, IRA).
• A failure to maintain an effective system of internal control over financial reporting could result in material misstatements.

Future Outlook

Kodiak Sciences anticipates topline data for the Phase 3 GLOW2 study in 1Q 2026 and for the Phase 3 DAYBREAK study in 3Q 2026. The company plans to file a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO in 2026, after the DAYBREAK data readout. Topline data for the Phase 3 PEAK and PINNACLE studies for KSI-101 are expected in 4Q 2026 and 1Q 2027, respectively. The company expects to continue incurring significant and increasing net losses for the foreseeable future and believes its existing cash may not be sufficient for the next 12 months, necessitating additional capital raises.

Management Comments

• We are a clinical stage biopharmaceutical company committed to researching, developing and commercializing transformative therapeutics to treat a broad spectrum of retinal diseases.
• Our ABC Platform uses molecular engineering to merge the fields of protein-based and chemistry-based therapies and has been at the core of Kodiak's discovery engine.
• We intend to file a single Biologics License Application (BLA) in wet AMD, DR and retinal vein occlusion (RVO) in 2026.
• Kodiak anticipates to be in a position to announce topline data for the primary endpoint for GLOW2 in 1Q 2026 and for the primary endpoint for DAYBREAK in 3Q 2026.
• Kodiak plans to wait for DAYBREAK topline data expected 3Q 2026 in order to file a single BLA for tarcocimab in wet AMD, DR and RVO.
• KSI-501 is designed to provide high immediacy/efficacy and high durability.
• We believe that MESI represents a new market segment separate from the established anti-VEGF market.
• Kodiak's leadership at the intersection of retinal biology, optics and artificial intelligence continues to advance.
• We believe that our current cash and cash equivalents will be sufficient to support our current and planned operations into 2026.
• We expect to continue to incur operating losses and negative operating cash flows for the foreseeable future and as a result, there is substantial doubt regarding our ability to continue as a going concern.

Industry Context

The retinal disease market is highly competitive, with established players like Roche (Vabysmo) and Regeneron (Eylea HD) having recently gained significant market share with new approvals. Kodiak Sciences is attempting to carve out a niche with its ABC Platform and bispecific therapies, aiming for extended durability and novel mechanisms of action beyond traditional anti-VEGF. The company's focus on MESI as a new market segment highlights an attempt to differentiate in a crowded space. However, the capital-intensive nature of drug development, coupled with the need for substantial additional financing and the inherent risks of clinical trials, places Kodiak in a challenging position against larger, more financially robust competitors.

Comparison to Industry Standards

• Roche's Vabysmo (faricimab) received FDA approval for wet AMD and DME in January 2022 and for RVO in October 2023, demonstrating rapid market adoption and significant market share capture.
• Regeneron's Eylea HD (high dose aflibercept) gained FDA approval for wet AMD, DME, and DR in August 2023, becoming an important therapy due to Regeneron's incumbent position.
• Kodiak's tarcocimab, despite some positive Phase 3 results (GLOW1, BEACON, DAYLIGHT), previously failed to meet primary efficacy endpoints in Phase 2b/3 DAZZLE and Phase 3 GLEAM/GLIMMER studies, with an unexpected increase in cataracts, contrasting with the more consistent success of competitors' recent approvals.
• The company's goal for tarcocimab to provide a flexible 1-month through 6-month label for all retinal vascular disease patients aims for a durability profile that would be highly competitive against existing therapies, but this is yet to be proven in the ongoing trials and approved by regulators.
• KSI-501 and KSI-101, targeting IL-6 and VEGF, represent an attempt to address disease biology beyond VEGF, potentially offering differentiated efficacy compared to current anti-VEGF monotherapies, which is a developing trend in the industry.

Legal Proceedings

• Management is not aware of any matters that could have a material adverse effect on its financial position, results of operations or cash flows as of the date of this report.

Related Party Transactions

• As of September 30, 2025, the fair value of the liability related to sale of future royalties is based on the Company's current estimates of future royalties expected to be paid to Baker Bros. Advisors, LP (BBA), which are considered Level 3 inputs.

Stakeholder Impact

• **Shareholders**: Significant dilution risk from potential future equity financings. Potential for substantial losses if the company fails to secure additional funding or if product candidates do not achieve regulatory approval and commercial success. The 'going concern' warning indicates a high risk of capital loss.
• **Employees**: Uncertainty regarding job security due to the company's financial condition and potential need to 'pause, scale back or discontinue' development programs. Competition for skilled personnel is intense, and the company's financial state may impact its ability to attract and retain talent.
• **Customers (future)**: Potential for new transformative therapeutics for retinal diseases if product candidates are successfully developed and commercialized. However, delays or failures in development could mean unmet medical needs persist.
• **Suppliers/Creditors**: Increased risk due to the company's 'going concern' doubt and reliance on third-party manufacturers and suppliers. Potential for delayed or non-payment if financial condition deteriorates further.
• **Regulatory Authorities**: Continued engagement for clinical trial oversight and future BLA submissions. The company's financial stability could impact its ability to meet regulatory requirements and timelines.

Next Steps

• Announce topline data for the Phase 3 GLOW2 study in 1Q 2026.
• Announce topline data for the Phase 3 DAYBREAK study in 3Q 2026.
• File a single Biologics License Application (BLA) for tarcocimab in wet AMD, DR, and RVO in 2026, following the DAYBREAK data readout.
• Continue active enrollment for the Phase 3 PEAK and PINNACLE studies for KSI-101.
• Announce topline data for the Phase 3 PEAK study in 4Q 2026.
• Announce topline data for the Phase 3 PINNACLE study in 1Q 2027.
• Progress dual cytokine-targeting bispecific antibody programs (KSI-102, KSI-103) through pre-IND activities.
• Advance retina duet programs (glaucoma, geographic atrophy) built with the ABC Platform towards IND.

Key Dates

Recommendation

The filing presents a dire financial situation with a 'substantial doubt' about the company's ability to continue as a going concern, driven by rapidly increasing net losses and a significant depletion of cash reserves. While clinical programs are advancing, the history of tarcocimab's prior Phase 3 failures (GLEAM/GLIMMER) and the highly competitive market for retinal diseases introduce considerable uncertainty. The explicit need for additional capital in a challenging economic climate, coupled with the risk of significant dilution or program curtailment, makes the investment highly speculative and risky. The current financial trajectory and explicit going concern warning outweigh the potential future upside of clinical progress, warranting a strong sell recommendation.

Keywords

Retinal diseases, Biopharmaceutical, Clinical stage, Tarcocimab, KSI-501, KSI-101, ABC Platform, Wet AMD, Diabetic Retinopathy, Retinal Vein Occlusion, Macular Edema Secondary to Inflammation, Anti-VEGF, Anti-IL-6, Bispecific therapy, Phase 3 clinical trials, BLA filing, Going concern, Net loss, Cash burn, R&D expenses, Biologics, Ocular inflammation, Glaucoma, Geographic atrophy, VETi program, AI in ophthalmology